Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|BO-264||BO264|BO 264||BO-264 is a small molecule drug that binds to and inhibits TACC3, which potentially induces mitotic arrest, increases DNA damage and apoptosis, and reduced cell viability, and inhibits tumor growth (PMID: 32217742).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FGFR3 - TACC3||urinary bladder cancer||sensitive||BO-264||Preclinical - Cell culture||Actionable||In a preclinical study, BO-264 treatment inhibited Erk1/2 phosphorylation, induced mitotic arrest, and reduced viability of a urinary bladder cancer cell line harboring FGFR3-TACC3 in culture (PMID: 32217742).||32217742|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|